Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.
Saved in:
| Title: | Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study. |
|---|---|
| Authors: | Langslet G; Lipid Clinic, Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital 0424, Oslo, Norway., Nyström T; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet 118 83, Stockholm, Sweden., Vistisen D; Clinical Epidemiology, Steno Diabetes Center Copenhagen 2730, Herlev, Denmark.; A/I and Analytics, Novo Nordisk A/S, AI and Analytics, Søborg, Denmark., Carstensen B; Clinical Epidemiology, Steno Diabetes Center Copenhagen 2730, Herlev, Denmark., Grip ET; Real World Data and Data Analytics, Quantify Research 11221, Stockholm, Sweden.; Department of Medicine, Karolinska Institutet 141 57, Huddinge, Sweden., Casajust P; Real-World Data and Data Analytics, TFS HealthScience 08007, Barcelona, Spain., Tskhvarashvili G; Global Database Studies, Real World Solutions, IQVIA 10119, Tallinn, Estonia., Hoti F; Global Database Studies, Real World Solutions, IQVIA 02130, Espoo, Finland., Klement R; Global Database Studies, Real World Solutions, IQVIA, 51013, Tartu, Estonia., Karlsdotter K; Market Access, Boehringer Ingelheim Pharmaceuticals 12032, Stockholm, Sweden., Tuovinen M; Global Medical Affairs, Boehringer Ingelheim Pharmaceuticals 00180, Helsinki, Finland., Ofstad AP; Type 2 Diabetes and Metabolism, Medical Department, Boehringer Ingelheim 1383, Oslo, KS, Norway.; Department of Medicine, Oslo Diabetes Research Center 0424, Oslo, Norway., Lajer M; Global Integrated Evidence, Boehringer Ingelheim Pharmaceuticals 2100, Copenhagen, Denmark., Shay C; Global Integrated Evidence, Boehringer Ingelheim Pharmaceuticals, Inc. 06877, Ridgefield, Connecticut, USA., Koeneman L; Diabetes Global Medical Affairs, Lilly Deutschland GmbH 61352, Bad Homburg, Germany., Farsani SF; Global Integrated Evidence, Boehringer Ingelheim International GmbH 55216, Ingelheim, Germany., Niskanen L; Päijät-Häme Joint Authority for Health and Wellbeing, Päijät-Häme Central Hospital 15850, Lahti, Finland.; Institute of Clinical Medicine, University of Eastern Finland 70210, Kuopio, Finland., Halvorsen S; Department of Cardiology, Oslo University Hospital Ullevål 0450, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo 0372, Oslo, Norway. |
| Source: | Journal of diabetes research [J Diabetes Res] 2024 Oct 12; Vol. 2024, pp. 6142211. Date of Electronic Publication: 2024 Oct 12 (Print Publication: 2024). |
| Publication Type: | Journal Article; Comparative Study; Multicenter Study |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101605237 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6753 (Electronic) NLM ISO Abbreviation: J Diabetes Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2314-6753 |
|---|---|
| DOI: | 10.1155/2024/6142211 |
